Naphcon A
NDC 52959-107
Product Information
Naphcon A is a NDA-approved product labeled by H.j. Harkins Company, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 52959-107 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 52959-107?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NAPHAZOLINE HYDROCHLORIDE (UNII: MZ1131787D)
- NAPHAZOLINE (UNII: H231GF11BV) (Active Moiety)
- PHENIRAMINE MALEATE (UNII: NYW905655B)
- PHENIRAMINE (UNII: 134FM9ZZ6M) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- WATER (UNII: 059QF0KO0R)
- SODIUM BORATE (UNII: 91MBZ8H3QO)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- BORIC ACID (UNII: R57ZHV85D4)
- EDETIC ACID (UNII: 9G34HU7RV0)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1043658 - naphazoline HCl 0.025 % / pheniramine maleate 0.3 % Ophthalmic Solution
- RxCUI: 1043658 - naphazoline hydrochloride 0.25 MG/ML / pheniramine maleate 3 MG/ML Ophthalmic Solution
- RxCUI: 1043658 - naphazoline hydrochloride 0.025 % / pheniramine maleate 0.3 % Ophthalmic Solution
- RxCUI: 1046266 - NAPHCON A 0.025 % / 0.3 % Ophthalmic Solution
- RxCUI: 1046266 - naphazoline hydrochloride 0.25 MG/ML / pheniramine maleate 3 MG/ML Ophthalmic Solution [Naphcon A]
* Please review the full disclaimer at the bottom of this page.